Kalaris Therapeutics, Inc.
KLRS
$3.08
$0.5220.31%
NASDAQ
| 06/30/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | -11.75% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 18.37% | ||||
| Operating Income | -18.37% | ||||
| Income Before Tax | -11.32% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -11.32% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -11.32% | ||||
| EBIT | -18.37% | ||||
| EBITDA | -- | ||||
| EPS Basic | 75.87% | ||||
| Normalized Basic EPS | 75.87% | ||||
| EPS Diluted | 75.87% | ||||
| Normalized Diluted EPS | 75.87% | ||||
| Average Basic Shares Outstanding | 361.41% | ||||
| Average Diluted Shares Outstanding | 361.41% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||